<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02875873</url>
  </required_header>
  <id_info>
    <org_study_id>basics001</org_study_id>
    <nct_id>NCT02875873</nct_id>
  </id_info>
  <brief_title>Balanced Solution Versus Saline in Intensive Care Study</brief_title>
  <acronym>BaSICS</acronym>
  <official_title>Balanced Solution Versus Saline in Intensive Care Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital do Coracao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Moinhos de Vento</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Sirio-Libanes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital do Coracao</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 2x2 factorial randomized study to evaluate the effect of a balanced crystalloid solution
      compared with 0.9% saline, and of rapid vs. slow infusion on clinical outcomes of critically
      ill patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pragmatic, multicenter, 2x2 factorial randomized study. Severe patients admitted to the ICU
      at moderate to high risk for death or acute kidney injury will be randomly allocated to
      receive a balanced crystalloid solution (Plasma-Lyte®) or 0.9% saline and to receive
      crystalloids by rapid bolus infusion (999 mL/h) or slow infusion (333 mL/h) whenever plasma
      expansion is needed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2017</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal failure requiring renal replacement therapy</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Injury (KDIGO equal or greater than 2)</measure>
    <time_frame>Days 3 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic, cardiac, neurological, coagulation, and respiratory dysfunctions (assessed by Sequential Organ Failure Assessment [SOFA] scores)</measure>
    <time_frame>Days 3 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation free days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Intensive Care Unit Mortality</measure>
    <time_frame>At ICU discharge, up to 90 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hospital Mortality</measure>
    <time_frame>At Hospital discharge, up to 90 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Length of Intensive Care Unit stay</measure>
    <time_frame>At ICU discharge, up to 90 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>At hospital discharge, up to 90 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life</measure>
    <time_frame>180 days</time_frame>
    <description>Assessed using EQ-5D. Will only be performed in a subsample of all included patients (10%)</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">11000</enrollment>
  <condition>Critical Illness</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Plasma-Lyte, Slow Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plasma-Lyte will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plasma-Lyte, Fast Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plasma-Lyte will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline 0.9%, Slow Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saline 0.9% will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline 0.9%, Fast Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saline 0.9% will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plasma-Lyte</intervention_name>
    <description>Plasma-Lyte will be used for fluid expansion and maintenance</description>
    <arm_group_label>Plasma-Lyte, Slow Infusion</arm_group_label>
    <arm_group_label>Plasma-Lyte, Fast Infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline 0.9%</intervention_name>
    <description>Saline 0.9% will be used for fluid expansion and maintenance</description>
    <arm_group_label>Saline 0.9%, Slow Infusion</arm_group_label>
    <arm_group_label>Saline 0.9%, Fast Infusion</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Slow infusion speed</intervention_name>
    <description>Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h. NOTE: This intervention will not be blinded.</description>
    <arm_group_label>Plasma-Lyte, Slow Infusion</arm_group_label>
    <arm_group_label>Saline 0.9%, Slow Infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fast Infusion Speed</intervention_name>
    <description>Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h. NOTE: This intervention will not be blinded.</description>
    <arm_group_label>Plasma-Lyte, Fast Infusion</arm_group_label>
    <arm_group_label>Saline 0.9%, Fast Infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (all three):

          1. Need for plasma expansion, and the clinician considers that Plasma-Lyte® or 0.9%
             saline are equally appropriate for patients, with no specific indications or
             contraindications for any of the fluids or for rapid or slow infusion.

          2. Patients not expected to be discharged on the day after their admission.

          3. At least one of the following risk factors for acute renal injury:

               1. Age ≥ 65 years

               2. Hypotension (mean arterial pressure [MAP] &lt; 65 mmHg or systolic blood pressure
                  [SBP] &lt; 90 mmHg) or use of vasopressors

               3. Sepsis

               4. Use of invasive mechanical ventilation or of continuous noninvasive mechanical
                  ventilation (including high-flow nasal cannula) &gt; 12 hours

               5. Oliguria (&lt; 0.5 mL/kg/hour for ≥ 3 hours)

               6. Serum creatinine ≥ 1.2 mg/dL for women or ≥ 1.4 mg/dL for men

               7. Liver cirrhosis or acute liver failure

        Exclusion Criteria (any of the below):

          1. Age &lt; 18 years

          2. Acute renal failure treated with renal replacement therapy (RRT) or expected to
             require RRT within the next 6 hours

          3. Severe hyponatremia (serum sodium ≤ 120 mmol/L)

          4. Severe hypernatremia (serum sodium ≥ 160 mmol/L)

          5. Hyperkalemia (serum potassium ≥ 5.5 mmol/L)

          6. Death considered imminent and inevitable within 24 hours

          7. Patients with suspected or confirmed brain death

          8. Patients under exclusive palliative care

          9. Patients previously enrolled in the BaSICS study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre B Cavalcanti, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital do Coracao</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando G Zampieri, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital do Coracao</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luciano CP Azevedo, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Sirio-Libanes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maicon Falavigna, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Moinhos de Vento</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nilton Brandao, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Moinhos de Vento</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Otavio Berwanger, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital do Coracao</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandre B Cavalcanti, MD, PhD</last_name>
    <phone>+551130536611</phone>
    <phone_ext>8102</phone_ext>
    <email>abiasi@hcor.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fernando G Zampieri, MD</last_name>
    <phone>+551130536611</phone>
    <phone_ext>8239</phone_ext>
    <email>fzampieri@hcor.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alexandre Biasi Cavalcanti</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>04005000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karina Normilio-Silva</last_name>
      <phone>55xx1130536611</phone>
      <phone_ext>8204</phone_ext>
      <email>knsilva@hcor.com.br</email>
    </contact>
    <contact_backup>
      <last_name>Alexandre B Cavalcanti, MD,PhD</last_name>
      <phone>55xx1130536611</phone>
      <phone_ext>8102</phone_ext>
      <email>abiasi@hcor.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Alexandre B Cavalcanti, MD.Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2016</study_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methamphetamine</mesh_term>
    <mesh_term>Plasma-lyte 148</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be publicly available two years after trial results have been published</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

